Chenglong Li

Chenglong Li, Ph.D.

Professor And The Nicholas Bodor Professor In Drug Discovery

Department: Medicinal Chemistry
Business Phone: (352) 294-8510

About Chenglong Li

Chenglong Li, Ph.D., obtained his B.Sc. in chemistry and M.Sc. in physical chemistry from Beijing University in 1985 and 1988, respectively. Following college, he worked at the Institute of Biophysics at the Chinese Academy of Sciences. He traveled to the United States and obtained his Ph.D. in biophysics at Cornell University, New York in 2000. He spent five years in San Diego, California, working as a postdoc in structural biology at the Burnham Institute for Medical Research (2000-2002) and as a research associate in computational chemistry at the Scripps Research Institute (2002-2005). Starting August 1, 2005, he moved to Columbus, Ohio as a tenure-track assistant professor in the Division of Medicinal Chemistry and Pharmacognosy at the College of Pharmacy, the Ohio State University, and rose through the ranks to associate professor with tenure in 2011 and full professor in 2016. In August 2016, he was appointed as the Nicholas Bodor Professor in Drug Discovery and professor of medicinal chemistry at the University of Florida.


2019 Journal of Experimental & Clinical Cancer Research
2017 Biochemical and Biophysical Research Communications


Jul 2020 ACTIVE
Chemistry-Biology Interface Training Program at the University of Florida
NATL INST OF HLTH NIGMS · Principal Investigator
Sep 2019 ACTIVE
QLCI-CG: Conceptualization of the Institute for Quantum Biology on Quantum Computers
Sep 2019 ACTIVE
Novel Targeted Anticancer Agents from Marine Cyanobacteria
Sep 2018 ACTIVE
Mechanistic studies of gamma-glutamyl transpeptidase inhibition: A novel approach to modulating serum levels of cysteine
UNIV OF OKLAHOMA · Principal Investigator
Jun 2017 ACTIVE
Role and targeting of PRMT5 in prostate cancer
PURDUE UNIV · Principal Investigator
Sep 2016 – Jan 2018
Repositioning Bazedoxifene as a novel IL-6/GP130 inhibitor for sarcoma therapy
UNIV OF MARYLAND · Principal Investigator
Aug 2016 – Apr 2019
Small molecule in vivo probe development targeting the IL-6/STAT3 pathway for potential multiple sclerosis therapy
NATL INST OF HLTH NINDS · Principal Investigator
Aug 2016 ACTIVE
A novel STAT3-selective inhibitor for medulloblastoma therapy
UNIV OF MARYLAND · Principal Investigator


2000 · Cornell University
1988 · Beijing University
1985 · Beijing University

Contact Details

(352) 294-8510